Daré Bioscience Management
Management criteria checks 4/4
Daré Bioscience's CEO is Sabrina Johnson, appointed in May 2015, has a tenure of 8.83 years. total yearly compensation is $801.08K, comprised of 64.8% salary and 35.2% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $173.98K. The average tenure of the management team and the board of directors is 9.5 years and 8.8 years respectively.
Key information
Sabrina Johnson
Chief executive officer
US$801.1k
Total compensation
| CEO salary percentage | 64.75% |
| CEO tenure | 11yrs |
| CEO ownership | 0.6% |
| Management average tenure | 9.5yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$12m |
| Dec 31 2025 | US$801k | US$519k | -US$13m |
| Sep 30 2025 | n/a | n/a | -US$17m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$898k | US$495k | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$1m | US$495k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$2m | US$466k | -US$31m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$2m | US$405k | -US$39m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$835k | US$368k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$629k | US$335k | -US$15m |
Compensation vs Market: Sabrina's total compensation ($USD801.08K) is about average for companies of similar size in the US market ($USD647.55K).
Compensation vs Earnings: Sabrina's compensation has been consistent with company performance over the past year.
CEO
Sabrina Johnson (58 yo)
Ms. Sabrina Martucci Johnson serves as Director at BIOCOM, Inc. since February 2021 and serves as its Chairman since January 2025. Ms. Johnson Founded Dar? Bioscience since 2015 and serves as its Chief Exe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 11yrs | US$801.08k | 0.55% $ 174.0k | |
| Chief Accounting Officer | 4.1yrs | US$546.86k | 0% $ 0 | |
| Vice President of Operations | 11.3yrs | no data | no data | |
| Chief Scientific Officer | 7.9yrs | no data | no data | |
| Vice President of Corporate Affairs & Development | no data | no data | no data |
Experienced Management: DARE's management team is seasoned and experienced (9.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President | 8.8yrs | US$801.08k | 0.55% $ 174.0k | |
| Independent Chairman of the Board | 12.3yrs | US$87.82k | 0.0059% $ 1.9k | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Independent Director | 11.6yrs | US$55.82k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$60.32k | 0.14% $ 44.5k | |
| Independent Director | 8.1yrs | US$59.32k | 0% $ 0 | |
| Independent Director | 7.7yrs | US$66.82k | 0.00029% $ 91.6 |
Experienced Board: DARE's board of directors are considered experienced (8.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/17 20:20 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daré Bioscience, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |